Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction.

Peters BJM., Rodin AS., Klungel OH., van Duijn CM., Stricker BHC., van't Slot R., de Boer A., Maitland-van der Zee A-H.

AimsGenetic variability within the SLCO1B1 and ABCB1 transporter genes has been associated with modification of statin effectiveness in cholesterol management.Materials & methodsWe conducted a case-control study using a population-based registry of pharmacy records linked to the hospital discharge records. Within a hypercholesterolemic cohort, we included 668 myocardial infarction cases and 1217 controls.ResultsWe tested 24 tagging SNPs and found two SNPs within ABCB1 (rs3789244, p = 0.01; rs1922242, p = 0.01) to interact with statin treatment. In addition, we found a nonsignificant haplotype-treatment interaction (p = 0.054). The odds ratio for subjects homozygous for SLCO1B1*1A was 0.49 (95% CI: 0.34-0.71) compared with 0.31 (95% CI: 0.24-0.41) for heterozygous or noncarriers of the *1A allele.ConclusionThis is the first study to demonstrate that common genetic variability within the SLCO1B1 and ABCB1 genes is associated with the modification of the effectiveness of statins in the prevention of the clinical outcome, myocardial infarction.

More information Original publication

DOI

10.2217/pgs.10.81

Type

Journal article

Publication Date

2010-08-01T00:00:00+00:00

Volume

11

Pages

1065 - 1076

Total pages

11

Addresses

F, a, c, u, l, t, y, , o, f, , S, c, i, e, n, c, e, ,, , D, i, v, i, s, i, o, n, , o, f, , P, h, a, r, m, a, c, o, e, p, i, d, e, m, i, o, l, o, g, y, , &, , P, h, a, r, m, a, c, o, t, h, e, r, a, p, y, ,, , U, t, r, e, c, h, t, , U, n, i, v, e, r, s, i, t, y, ,, , U, t, r, e, c, h, t, ,, , T, h, e, , N, e, t, h, e, r, l, a, n, d, s, .

Keywords

Humans, Myocardial Infarction, Organic Anion Transporters, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Treatment Outcome, Medical Records, Incidence, Logistic Models, Case-Control Studies, Pharmacogenetics, Haplotypes, Polymorphism, Single Nucleotide, Middle Aged, Female, Male, ATP Binding Cassette Transporter, Subfamily B, ATP Binding Cassette Transporter, Subfamily B, Member 1, Liver-Specific Organic Anion Transporter 1